Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) ...
News Medical on MSN3d
Dual-targeted therapy plus chemo boosts response rate in BRAF-mutated metastatic colorectal cancer
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the ...
Science Daily5d
Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...
Cure Today4d
The BREAKWATER Trial Explores Braftovi, Erbitux and Chemo in BRAF V600E+ mCRC
Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...
Cure Today4d
Study Shows Poor Outcomes in BRAF V600E-Mutant Metastatic CRC
BRAF V600E-mutant metastatic colorectal cancer (CRC) was associated with poor clinical outcomes in patients receiving ...
appliedclinicaltrialsonline2d
Pfizer Shares Positive Data from Phase III BREAKWATER Trial of Braftovi Combination Following Accelerated Approval
Being evaluated for the treatment of metastatic colorectal cancer, the combination regimen achieved an objective response ...
Medical Xpress3d
Dual-targeted therapy plus chemo boosts response rate in BRAF-mutated metastatic colorectal cancer
In patients with BRAF V600E-mutant metastatic colorectal cancer, a combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy showed a 60.9% overall response rate, outperforming the 40% ...